In the latest quarter, 10 analysts provided ratings for Myriad Genetics (NASDAQ:MYGN), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...
Providers and Patients Benefit by Pairing AI-Powered Tools with Human Expertise to Increase Payment Completion at Time of Treatment Myriad Systems, a leader in healthcare practice management, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results